
Haystack MRD™: Proven clinical utility
The landmark DYNAMIC study is the first prospective, randomized, interventional trial to demonstrate the clinical benefit of MRD testing to guide adjuvant therapy
HomeIndustry News
The landmark DYNAMIC study is the first prospective, randomized, interventional trial to demonstrate the clinical benefit of MRD testing to guide adjuvant therapy
Haystack MRD™ strikes the right balance of DNA molecules interrogated and number of mutations tracked for optimizing test efficiency and sustainability
Social:
Joel has overseen financial and business operations for multiple life sciences companies. Most recently, he served as Vice President of Finance & Corporate Development at Sema4, an AI-focused precision medicine company. Previously, Mr. Kaufman served as Chief Business Officer, at Navidea Biopharmaceuticals. He also served as an Equity Research Analyst at Goldman Sachs covering the Life Science Tools, Diagnostics, and Medical Technology sectors. Mr. Kaufman holds an MBA from Northwestern University’s Kellogg School of Management and a BA from the University of Pennsylvania.
Social:
Social:
Jen serves as the Director of Pharma Partnering and Strategic Alliances at Haystack Oncology, where she facilitates key collaborations to bring the promise of precision medicine closer to patients. Jen has a background in law, as well as oncology diagnostics and drug development, previously serving in roles at Sysmex Inostics, Natera, and PGDx/Labcorp. Leading with the philosophy that a culture of collaboration is the path forward to improving cancer patient care, Jen engages closely with pharma and healthcare systems to support their research and clinical development programs. Jen holds degrees from Georgetown University and Suffolk University Law School and has over a decade of experience in operations and business development.
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social: